OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Energenesis Biomedical Co OCF Yield % Related Terms
Energenesis Biomedical Co OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6657 vs VRTX, REGN, ALNY: OCF Yield % Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Energenesis Biomedical Co (TPE:6657) has a OCF Yield % of -6.81 as of Jul. 05, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Energenesis Biomedical Co and its competitors. According to the industry distribution chart, Energenesis Biomedical Co ranks #663 out of 1410 companies in the Biotechnology industry, placing it in the top 47%.
Is Energenesis Biomedical Co's OCF Yield % too high?
Energenesis Biomedical Co's current OCF Yield % is -6.81. Based on the distribution chart, Energenesis Biomedical Co ranks #663 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Energenesis Biomedical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's OCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #663 out of 1410 companies for OCF Yield %. This puts Energenesis Biomedical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Energenesis Biomedical Co and its competitors. Energenesis Biomedical Co's current OCF Yield % is -6.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$37.15 — trading 27.7% below its estimated fair value. The current OCF Yield % is -6.81. Energenesis Biomedical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current OCF Yield % is -6.81 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$37.15 is trading 27.7% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Energenesis Biomedical Co to be Modestly Undervalued.
Key valuation signals for TPE:6657:
OCF Yield %: -6.81
GF Value™: NT$51.35 vs. price of NT$37.15 (27.7% below fair value)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
63GF Score
Get the complete analysis for TPE:6657
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
